Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: The Molecular Tumor Board Portal.


  1. Rieke, D. T. et al. JCO Precis. Oncol. 2, 1–14 (2018).

    Google Scholar 

  2. Eggermont, A. M. M. et al. Mol. Oncol. 13, 521–527 (2019).

    Article  Google Scholar 

  3. Wagner, A. H. et al. Nat. Genet. 52, 448–457 (2020).

    CAS  Article  Google Scholar 

  4. Richards, S. et al. Genet. Med. Off. J. Am. Coll. Med. Genet. 17, 405–424 (2015).

    Google Scholar 

  5. Landrum, M. J. et al. Nucleic Acids Res. 46, D1062–D1067 (2018).

    CAS  Article  Google Scholar 

  6. Cline, M. S. et al. PLoS Genet. 14, e1007752 (2018).

    Article  Google Scholar 

  7. Griffith, M. et al. Nat. Genet. 49, 170–174 (2017).

    CAS  Article  Google Scholar 

  8. Tamborero, D. et al. Genome Med. 10, 25 (2018).

    Article  Google Scholar 

  9. Chakravarty, D. et al. JCO Precis. Oncol. 1, 1–16 (2017).

    Google Scholar 

  10. Mateo, J. et al. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 29, 1895–1902 (2018).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations



Corresponding authors

Correspondence to David Tamborero or Janne Lehtiö.

Ethics declarations

Competing interests

D. T. reports consultant and/or advisory fees from Roche. R. D. reports receiving honoraria for speaker activities from Roche, Ipsen, Amgen, Sanofi, Servier Laboratories and Merck Sharp & Dohme; an advisory role at Roche and Boehringer Ingelheim; and research grants from Merck and Pierre Fabre. R. B. reports consultant or advisory roles (with funding to the institution) at AstraZeneca, Daiichi-Sankyo, Lilly, Molecular Partners, Novartis, Roche and Shionogi; is a principal or sub-investigator of clinical trials for Astex, AstraZeneca, Boehringer-Ingelheim, Boston Therapeutics, Genentech/Roche, Johnson & Johnson, Lilly, Molecular Partners, PharmaMar, Roche, Sanofi-Aventis, Shionogi and Taiho; and reports research grants from AstraZeneca, Boehringer-Ingelheim and Genentech. I. B. reports a consultant or advisory role at Orion Pharma and speaker activities for Bristol Myers Squibb; reports travel grants from AstraZeneca and Merck Serono; and is a principal investigator of clinical trials for AstraZeneca, Bristol Myers Squibb, Celgene, Gliknik, GlaxoSmithKline, Janssen, Kura, Merck, Sharp & Dohme, Novartis, Orion Pharma, Pfizer, Shattuck, Northern Biologics, Rakutan Aspirian and Nanobiotics. C. M. reports consultant and/or advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck, Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, Orion; and is a principal or sub-investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, Bristol Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GlaxoSmithKline, H3 biomedicine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, Merck, Sharp & Dohme, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro and Xencor. R. S. reports research funding from Pfizer, AstraZeneca, PharmaMar, Roche and Daiichi Sankyo; speaker honoraria from Pfizer, Daiichi Sankyo and Novartis; and participation in advisory boards at Pfizer, Daiichi Sankyo and Novartis. E. G. reports consultant honoraria from Roche/Genentech, F. Hoffmann La Roche, Ellipses Pharma, Neomed Therapeutics, Boehringer Ingelheim–Janssen Global Services, AstraZeneca, SeaGen, TFS–Alkermes; reports research for Novartis/Roche; is a principal or sub-investigator of clinical trials for Principia Biopharma, Lilly, Novartis Farmacéutica, Genentech, Loxo Oncology, F. Hoffmann La Roche, Symphogen, Merck, Sharp & Dohme de España, Incyte Biosciences International, Pharma Mar, Kura Oncology, Macrogenics, Glycotope, Pierre Fabre Medicament, Cellestia Biotech, Menarini Ricerche Spa, Blueprint Medicines, Beigene Usa, Sierra Oncology and Genmab; reports travel grants from Bristol-Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope; and is on the speakers bureau for Bristol-Mayers Squibb, Merck Sharp & Dohme, Roche and ThermoFisher. S. F. reports a consulting or advisory role, having received honoraria, research funding, and/or travel/accommodation expenses funding from Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca, and Pfizer. A. E. has received personal fees from Actelion, Agenus, Amgen, Bayer, Bristol Myers Squibb, Catalym, CellDex, Gilead, GlaxoSmithKline, HalioDX, Incyte, IO Biotech, ISA Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Nektar, Novartis, Pfizer, Polynoma, Regeneron, Sanofi and SkylineDx; and has equity in RiverDx, SkylineDx and Theranovir. E. E. V. is legally responsible for all contracts with pharmaceutical companies, as medical director of the Netherlands Cancer Institute. C. C. is a member of the External Science Panel of AstraZeneca and of Illumina’s Scientific Advisory Board, and his laboratory has received research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca and Servier. J. T. provides a scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Genmab, Halozyme, Imugene, Inflection Biosciences, Ipsen, Kura Oncology, Lilly, Merck Sharp & Dohme, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign, Rafael Pharmaceuticals, F. Hoffmann La Roche, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. J. R. reports research funding from Bayer & Novartis; clinical research for Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAlta, Pfizer, GenMab, CytomX, KELUN-BIOTECH, Takeda-Millennium, GlaxoSmithKline and Ipsen; is on the scientific advisory board of Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceuticals/Klus Pharma, Spectrum Pharmaceuticals, Pfizer, Roche Pharmaceuticals and Ellipses Pharma; and reports research funding for Bayer & Novartis. J. L. reports research funding from AstraZeneca, Novartis and GE healthcare; and is a co-founder and shareholder of FenoMark Diagnostics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tamborero, D., Dienstmann, R., Rachid, M.H. et al. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med 26, 992–994 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing